2-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}acetic acid | 1208229-65-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}acetic acid
• 英文别名: 2-[[2-[(E)-4-methoxy-4-oxobut-2-enoyl]oxyacetyl]amino]acetic acid
• CAS: 1208229-65-5
• 化学式: C₉H₁₁NO₇
• 分子量: 245.189
• InChiKey: DWYJAVLQLQZVRF-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (N-{[(tert-butyl)oxycarbonyl]methyl}carbamoyl)methyl methyl (2E)-but-2-ene-1,4-dioate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以0.13 g的产率得到2-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}acetic acid
  参考文献：
  名称：

  Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use

  摘要：

  甲基氢富马酸酯前药、包含甲基氢富马酸酯前药的药物组合物，以及使用甲基氢富马酸酯前药和药物组合物治疗牛皮癣、哮喘、多发性硬化症、炎症性肠病和关节炎等疾病的方法被披露。

  公开号：

  EP2650279A3

文献信息

• PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Gangakhedkar Archana

  公开号：US20100048651A1

  公开（公告）日：2010-02-25

  Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

  本发明公开了甲基氢富马酸的前药、包含甲基氢富马酸前药的药物组合物，以及利用甲基氢富马酸前药和药物组合物治疗牛皮癣、哮喘、多发性硬化、炎症性肠病和关节炎等疾病的方法。
• METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS
  申请人：XenoPort, Inc.

  公开号：US20150038499A1

  公开（公告）日：2015-02-05

  Methods of improving patient safety and reducing undesirable side effects for patients considering therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. In particular, a method of treating a disease in a patient in need of such treatment is provided. The method comprises testing the patient for a propensity for a deficiency in tissue glutathione S-transferase theta 1 enzyme (GSTT1) levels. Thereafter, a therapeutically effective amount of a compound selected from monomethyl fumarate (MMF), a prodrug of monomethyl fumarate, and combinations thereof is administered to the patient. During the treatment of the disease, blood lymphocyte concentration is periodically tested in the patient at a predetermined time interval length that is based on the enzyme level propensity testing result.

  本发明涉及改善患者安全和减少治疗使用单甲基富马酸及其前药所产生的不良副作用的方法。具体而言，本发明提供了一种治疗患者疾病的方法。该方法包括对患者进行组织谷胱甘肽S-转移酶θ1酶（GSTT1）水平缺陷的倾向性测试。随后，向患者施用单甲基富马酸（MMF）、单甲基富马酸前药或其组合的治疗有效量。在治疗疾病期间，以基于酶水平倾向性测试结果的预定时间间隔长度定期检测患者的血淋巴细胞浓度。
• METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：Gangakhedkar Archana

  公开号：US20120095003A1

  公开（公告）日：2012-04-19

  Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

  本发明涉及甲基氢富马酸的前药、包含甲基氢富马酸前药的制药组合物以及使用甲基氢富马酸前药和制药组合物治疗诸如银屑病、哮喘、多发性硬化症、炎症性肠病和关节炎等疾病的方法。
• Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof
  申请人：Gangakhedkar Archana

  公开号：US08785443B2

  公开（公告）日：2014-07-22

  Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

  本发明公开了甲基氢富马酸的前药、包含甲基氢富马酸前药的制药组合物，以及使用甲基氢富马酸前药和制药组合物治疗诸如牛皮癣、哮喘、多发性硬化症、炎症性肠病和关节炎等疾病的方法。
• Pharmaceutical Compositions Containing Dimethyl Fumarate
  申请人：Biogen Idec MA Inc.

  公开号：US20130295169A1

  公开（公告）日：2013-11-07

  Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

  本文提供了含有化合物或药学上可接受的盐的组合物，这些化合物代谢成具有特定药代动力学参数的单甲基富马酸酯，并且提供了使用这些组合物在受试对象中治疗、预防或缓解神经退行性疾病，包括多发性硬化症的方法。如果组合物含有二甲基富马酸酯，则二甲基富马酸酯的总量在组合物中的含量范围为约43% w/w至约95% w/w。